Gastrointestinal stromal tumor medical therapy: Difference between revisions
Jump to navigation
Jump to search
Varun Kumar (talk | contribs) Created page with "{{Gastrointestinal stromal tumor}} {{CMG}} ==Medical Therapy== Most small GISTs (<5 and especially <2 cm) with a low rate of mitosis (<5 dividing cells per 50 high-power ..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Gastrointestinal stromal tumor}} | {{Gastrointestinal stromal tumor}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
==Medical Therapy== | ==Medical Therapy== | ||
Most small GISTs (<5 and especially <2 cm) with a low rate of [[mitosis]] (<5 dividing cells per 50 high-power fields) are benign and,after surgery, do not require adjuvant therapy. | * Most small GISTs (<5 and especially <2 cm) with a low rate of [[mitosis]] (<5 dividing cells per 50 high-power fields) are [[benign]] and,after surgery, do not require [[adjuvant therapy]]. | ||
Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 [[mitosis|mitoses]]/50 HPF), may disseminate and/or recur. | * Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 [[mitosis|mitoses]]/50 HPF), may disseminate and/or recur. | ||
Until recently, GISTs were notorious for being resistant to [[chemotherapy]], with a success rate of <5%. Recently, the ''c-kit'' [[tyrosine kinase]] inhibitor [[imatinib]], a drug initially marketed for [[chronic myelogenous leukemia]], was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases. | * Until recently, GISTs were notorious for being resistant to [[chemotherapy]], with a success rate of <5%. Recently, the ''c-kit'' [[tyrosine kinase]] inhibitor [[imatinib]], a drug initially marketed for [[chronic myelogenous leukemia]], was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases. | ||
Patients who become refractory on imatinib may respond to the multiple tyrosine kinase inhibitor [[sunitinib]] (marketed as Sutent). | * Patients who become refractory on imatinib may respond to the multiple tyrosine kinase inhibitor [[sunitinib]] (marketed as Sutent). | ||
==References== | ==References== | ||
| Line 17: | Line 20: | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Disease]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 19:00, 12 September 2012
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor medical therapy On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor medical therapy |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
- Most small GISTs (<5 and especially <2 cm) with a low rate of mitosis (<5 dividing cells per 50 high-power fields) are benign and,after surgery, do not require adjuvant therapy.
- Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 mitoses/50 HPF), may disseminate and/or recur.
- Until recently, GISTs were notorious for being resistant to chemotherapy, with a success rate of <5%. Recently, the c-kit tyrosine kinase inhibitor imatinib, a drug initially marketed for chronic myelogenous leukemia, was found to be useful in treating GISTs, leading to a 40-70% response rate in metastatic or inoperable cases.
- Patients who become refractory on imatinib may respond to the multiple tyrosine kinase inhibitor sunitinib (marketed as Sutent).